DRAXIS Radiopharmaceutical Unit, DRAXIMAGE: Received USFDA Approval to Run 2 Clinical Trials for Neuroblastoma Treatment
DRAXIS Health Inc. (TSX: DAX, NASDAQ: DRAX)’s radiopharmaceutical business unit – DRAXIMAGE – received USFDA approval to conduct two clinical trials using radioactive Iobenguane I-131 Injection (also known as (131)I metaiodobenzylguanidine, or I-131 MIBG) for the treatment of high-risk neuroblastoma. 
The two clinical trials will be as follows:
Neuroblastoma is a rare form of cancer affecting mostly infants and young children.
The abovementioned clinical trials will be coordinated by a group of 11 children's hospitals and two universities in the United States known as the New Advances in Neuroblastoma Therapy (NANT) consortium and are expected to commence in December 2006 or early 2007.
Read the full press release.
Comment Preview